Noxopharm Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Noxopharm has a total shareholder equity of A$6.6M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$7.2M and A$580.8K respectively.

Informazioni chiave

Rapporto debito/patrimonio netto

AU$0

Debito

Indice di copertura degli interessi	n/a
Contanti	AU$5.16m
Patrimonio netto	AU$6.58m
Totale passività	AU$580.77k
Totale attività	AU$7.16m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Analisi della posizione finanziaria

Passività a breve termine: NOXO.F's short term assets (A$6.4M) exceed its short term liabilities (A$499.5K).

Passività a lungo termine: NOXO.F's short term assets (A$6.4M) exceed its long term liabilities (A$81.3K).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: NOXO.F is debt free.

Riduzione del debito: NOXO.F has no debt compared to 5 years ago when its debt to equity ratio was 56.9%.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: NOXO.F has less than a year of cash runway based on its current free cash flow.

Previsione Cash Runway: NOXO.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 1.2% each year

Noxopharm Salute del bilancio

Salute finanziaria criteri di controllo 4/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Noxopharm Limited, Annual General Meeting, Nov 19, 2024

Noxopharm Limited, Annual General Meeting, Nov 16, 2023

Noxopharm Limited Reviews Safety Data from the Third Cohort of Patients from the Dose Escalation Part of the DARRT-2 Trial

Noxopharm Limited Announces Award of Federal Innovation Connections Grant

Noxopharm Limited Announces CEP-2 Safety Milestone Shows Veyonda Progress

Noxopharm Limited Announces Resignation of Dr. Graham Kelly as Non-Executive Director, Effective 20 September 2022

Noxopharm Limited, Annual General Meeting, Nov 17, 2022

Noxopharm Limited Reviews the Safety Data from the First Cohort of Patients in the Trial

Noxopharm Limited Announces DARRT-2 Trial Safety Milestone and European Site Activated

Noxopharm Limited Announces Mayo Clinic and Washington University Join Its Sarcoma Trial

Veyonda Abstract Published at ASCO Annual Meeting 2022

FDA Grants Orphan Drug Designation to Noxopharm for Sarcoma Treatment

Noxopharm Limited Announces Phase 1 CEP-2 Sarcoma Trial is Underway with a First Patient Enrolled and Dosed At City of Hope in Los Angeles, California

Noxopharm Limited Announces First Patient Dosed in CEP-2 Sarcoma Trial at the US City of Hope Cancer Center

Noxopharm Limited Announces Veyonda Achieves Important U.S. Patent Claims

Noxopharm Announces Preclinical Data Further Supports Anti-Inflammatory Role of Idronoxil in the Treatment of COVID-19

Noxopharm Phase I Clinical Trial Shows Anti-Inflammatory Response in COVID-19 Patients

Noxopharm Limited Releases Preliminary Top Line Data of Its NOXCOVID Phase 1 Clinical Trial

Noxopharm Limited's DARRT-2 Study Receives IND Approval from FDA

Noxopharm Limited Updates the Market on Progress with its DARRT-2 Trial

Noxopharm Limited Announces the Release of Clinical Data Relating to the Experimental Radioligand

Noxopharm Limited Announces New Independent Trial Data Supports Potential of Veyonda as Major New Anti-Cancer Drug

Noxopharm Limited’s Veyonda to Begin First-Line Sarcoma Treatment Testing

Oxopharm Limited Announces That Its Cep-2 Study Will Open Shortly

Clinical Data Shows Noxopharm’s Veyonda May Prevent Cytokine Storm

Noxopharm IONIC Immuno-Oncology Trial Commences

Noxopharm Limited Announces Veyonda Approved to Move into Second and Final Stage of the NOXCOVID-1 Clinical Trial on the Advice of the Clinicians Treating the NOXCOVID-1 Patients

Noxopharm Limited Provides More Detailed Summary of Data from the Lupin Study That Formally Presented to the American Society of Clinical Oncology Genitourinary Cancers Symposium

Noxopharm Limited Reports the Publication in Abstract Form of the Latest Survival Data from the LuPIN Study

Noxopharm Limited Announces the Latest Formal Review by the NOXCOVID-1 Safety Steering Committee Cleared it to Advance to the Fifth and Final Dosage Cohort

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane